These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16971782)

  • 1. [PET (positron emission tomography) research on schizophrenia].
    Takano A; Suhara T
    Nihon Yakurigaku Zasshi; 2006 Sep; 128(3):177-83. PubMed ID: 16971782
    [No Abstract]   [Full Text] [Related]  

  • 2. A positron emission tomography occupancy study of brexpiprazole at dopamine D
    Girgis RR; Forbes A; Abi-Dargham A; Slifstein M
    Neuropsychopharmacology; 2020 Apr; 45(5):786-792. PubMed ID: 31847007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and evaluation of benzo[a]thieno[3,2-g]quinolizines as novel l-SPD derivatives possessing dopamine D1, D2 and serotonin 5-HT1A multiple action profiles.
    Li Z; Huang J; Sun H; Zhou S; Guo L; Zhou Y; Zhen X; Liu H
    Bioorg Med Chem; 2014 Nov; 22(21):5838-46. PubMed ID: 25308766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol.
    Reimold M; Solbach C; Noda S; Schaefer JE; Bartels M; Beneke M; Machulla HJ; Bares R; Glaser T; Wormstall H
    Psychopharmacology (Berl); 2007 Feb; 190(2):241-9. PubMed ID: 17111172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ITI-007 demonstrates brain occupancy at serotonin 5-HT₂A and dopamine D₂ receptors and serotonin transporters using positron emission tomography in healthy volunteers.
    Davis RE; Vanover KE; Zhou Y; Brašić JR; Guevara M; Bisuna B; Ye W; Raymont V; Willis W; Kumar A; Gapasin L; Goldwater DR; Mates S; Wong DF
    Psychopharmacology (Berl); 2015 Aug; 232(15):2863-72. PubMed ID: 25843749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent evidence for dopamine abnormalities in schizophrenia.
    Abi-Dargham A
    Eur Psychiatry; 2002 Aug; 17 Suppl 4():341s-347s. PubMed ID: 23573603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognition and Dopamine D
    Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC; Graff-Guerrero A
    Am J Geriatr Psychiatry; 2017 Jan; 25(1):1-10. PubMed ID: 27745822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous in-vivo receptor occupancy assays for serotonin 1A, 2A, and dopamine 2 receptors with the use of non-radiolabelled tracers: Proposed method in screening antipsychotics.
    Thentu JB; Nirogi R; Bhyrapuneni G; Ajjala DR; Aleti RR; Palacharla RC
    J Pharmacol Toxicol Methods; 2017; 85():22-28. PubMed ID: 28063918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
    Mamo D; Graff A; Mizrahi R; Shammi CM; Romeyer F; Kapur S
    Am J Psychiatry; 2007 Sep; 164(9):1411-7. PubMed ID: 17728427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia.
    Gründer G; Landvogt C; Vernaleken I; Buchholz HG; Ondracek J; Siessmeier T; Härtter S; Schreckenberger M; Stoeter P; Hiemke C; Rösch F; Wong DF; Bartenstein P
    Neuropsychopharmacology; 2006 May; 31(5):1027-35. PubMed ID: 16237387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
    Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
    Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Striatal dopamine D1 and D2 receptor balance in twins at increased genetic risk for schizophrenia.
    Hirvonen J; van Erp TG; Huttunen J; Någren K; Huttunen M; Aalto S; Lönnqvist J; Kaprio J; Cannon TD; Hietala J
    Psychiatry Res; 2006 Jan; 146(1):13-20. PubMed ID: 16361088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.
    Kegeles LS; Slifstein M; Frankle WG; Xu X; Hackett E; Bae SA; Gonzales R; Kim JH; Alvarez B; Gil R; Laruelle M; Abi-Dargham A
    Neuropsychopharmacology; 2008 Dec; 33(13):3111-25. PubMed ID: 18418366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator.
    Maeda K; Lerdrup L; Sugino H; Akazawa H; Amada N; McQuade RD; Stensbøl TB; Bundgaard C; Arnt J; Kikuchi T
    J Pharmacol Exp Ther; 2014 Sep; 350(3):605-14. PubMed ID: 24947464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.
    Sun H; Zhu L; Yang H; Qian W; Guo L; Zhou S; Gao B; Li Z; Zhou Y; Jiang H; Chen K; Zhen X; Liu H
    Bioorg Med Chem; 2013 Feb; 21(4):856-68. PubMed ID: 23332346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The dopaminergic hypothesis revisited].
    Guillin O
    Encephale; 2006 Oct; 32(5 Pt 4):S908-11; discussion S912. PubMed ID: 17119503
    [No Abstract]   [Full Text] [Related]  

  • 17. 5-HT1A receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson's disease and schizophrenia.
    Haleem DJ
    Behav Pharmacol; 2015 Feb; 26(1-2):45-58. PubMed ID: 25503261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography.
    Hietala J; Syvälahti E; Vuorio K; Någren K; Lehikoinen P; Ruotsalainen U; Räkköläinen V; Lehtinen V; Wegelius U
    Arch Gen Psychiatry; 1994 Feb; 51(2):116-23. PubMed ID: 7905257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.
    Kapur S; Zipursky R; Jones C; Shammi CS; Remington G; Seeman P
    Arch Gen Psychiatry; 2000 Jun; 57(6):553-9. PubMed ID: 10839333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia.
    Kegeles LS; Abi-Dargham A; Frankle WG; Gil R; Cooper TB; Slifstein M; Hwang DR; Huang Y; Haber SN; Laruelle M
    Arch Gen Psychiatry; 2010 Mar; 67(3):231-9. PubMed ID: 20194823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.